



WESTMINSTER
HEALTH FORUM

Next steps for NICE, priorities for the pharmaceutical industry, and the Accelerated Access Review 14th January 2016

CONDITIONS FOR USE OF TRANSCRIPTS:

This document is intended to provide a timely reference for interested parties who are unable to attend the event to which it refers. Some portions are based on transcripts of proceedings and others consist of text submitted by speakers or authors, and are clearly marked as such. As such, apart from where it is indicated that the text was supplied by the speaker, it has not been possible for the transcript to be checked by speakers and so this portion of the document does not represent a formal record of proceedings. Despite best endeavours by Westminster Forum Projects and its suppliers to ensure accuracy, text based on transcription may contain errors which could alter the intended meaning of any portion of the reported content. Anyone who intends to publicly use or refer to any text based on the transcript should make clear that speakers have not had the opportunity for any corrections, or check first with the speaker in question. If in doubt please contact the forum first.

Contents

<u>About this Publication</u>	3
<u>Agenda</u>	4
<u>Session Chair's opening remarks</u>	
Andrea Jenkyns MP , Member, Health Select Committee and Chair, All-Party Parliamentary Group on Patient Safety (<i>transcript</i>)	6
<u>Priorities for NICE in health and social care</u>	
Professor Gillian Leng , Deputy Chief Executive and Director of Health and Social Care, NICE (<i>transcript</i>)	7
Questions and comments from the floor (<i>transcript</i>)	12
<u>Implementing NICE guidelines: clarity, enforcement and reducing local variations</u>	
Ray Ghouse , Senior Health Economist, Boehringer Ingelheim (<i>text to be submitted by speaker</i>)	17
<u>The impact and role of NICE guidelines in care provision and health services</u>	
Amanda Edwards , Director of Knowledge and Evidence and Deputy Chief Executive, Social Care Institute for Excellence and Director, NICE Collaborating Centre for Social Care (<i>transcript</i>)	18
James Roach , Joint Director of Integration, Wiltshire Council and Wiltshire Clinical Commissioning Group (<i>transcript</i>)	20
Hannah Winter , Member, Executive Group, Patients Involved in NICE and Head of Policy and Programmes, Roald Dahl's Marvellous Children's Charity (<i>transcript</i>)	23
Questions and comments from the floor with Ray Ghouse , Senior Health Economist, Boehringer Ingelheim (<i>transcript</i>)	25
<u>Session Chair's closing remarks</u>	
Andrea Jenkyns MP , Member, Health Select Committee and Chair, All-Party Parliamentary Group on Patient Safety (<i>transcript</i>)	31
<u>Session Chair's opening remarks</u>	
Daniel Zeichner MP , Vice Chair, All-Party Parliamentary Group for Life Sciences (<i>transcript</i>)	32
<u>The Accelerated Access Review and next steps for improving market access</u>	
Nicole Mather , Director, Office for Life Sciences and Lead, Accelerated Access Review (<i>transcript</i>)	33
Questions and comments from the floor (<i>transcript</i>)	37
<u>Priorities for NHS pharmaceutical procurement: early access, fair pricing and sustainability</u>	
Professor Karl Claxton , Professor of Economics, University of York and former Member, NICE Appraisal Committee (<i>transcript</i>)	42
<u>Challenges for improving access to care and priorities for the Pharmaceutical Price Regulation Scheme</u>	
Paul Catchpole , Director of Value and Access, ABPI (<i>transcript</i>)	45
<u>The future for the Cancer Drugs Fund: access, value and evidence based strategies</u>	
Julia Manning , Chief Executive, 2020health (<i>transcript</i>)	48
Questions and comments from the floor (<i>transcript</i>)	51
<u>Concluding remarks</u>	
Professor Gillian Leng , Deputy Chief Executive and Director of Health and Social Care, NICE (<i>transcript</i>)	59
<u>Session Chair's and Westminster Health Forum closing remarks</u>	
Daniel Zeichner MP , Vice Chair, All-Party Parliamentary Group for Life Sciences (<i>transcript</i>)	61
Sam Dolton , Associate Producer, Westminster Health Forum (<i>transcript</i>)	62
<u>Press Links</u>	63
<u>Comments</u>	64
Dr Richard White , Director/Honorary Research Associate, Oxford PharmaGenesis/Oxford Brookes University	
Dr Hugh McIntyre , Consultant Physician, East Sussex Healthcare NHS Trust	
<u>List of Delegates Registered for Seminar</u>	66
<u>Contributor Biographies</u>	74
<u>About the Core Sponsor of the Westminster Health Forum</u>	77

Please be advised that speakers' PowerPoint presentations are included within the transcript itself, just beneath the relevant speaker's text. Please note that not all speakers are able to grant permission for us to include their slides.

Westminster Health Forum Keynote Seminar: Next steps for NICE, priorities for the pharmaceutical industry, and the Accelerated Access Review

Timing: Morning, Thursday, 14th January 2016

Venue: Royal Society, 6-9 Carlton House Terrace, London SW1Y 5AG



WESTMINSTER
HEALTH FORUM

- 8.30 - 9.00 Registration and coffee
- 9.00 - 9.05 **Session Chair's opening remarks**
Andrea Jenkyns MP, Member, Health Select Committee and Chair, All-Party Parliamentary Group on Patient Safety
- 9.05 - 9.40 **Priorities for NICE in health and social care**
Professor Gillian Leng, Deputy Chief Executive and Director of Health and Social Care, NICE
Questions and comments from the floor
- 9.40 - 9.50 **Implementing NICE guidelines: clarity, enforcement and reducing local variations**
Ray Ghouse, Senior Health Economist, Boehringer Ingelheim
- 9.50 - 10.40 **The impact and role of NICE guidelines in care provision and health services**
Amanda Edwards, Director of Knowledge and Evidence and Deputy Chief Executive, Social Care Institute for Excellence and Director, NICE Collaborating Centre for Social Care
James Roach, Joint Director of Integration, Wiltshire Council and Wiltshire Clinical Commissioning Group
Hannah Winter, Member, Executive Group, Patients Involved in NICE and Head of Policy and Programmes, Roald Dahl's Marvellous Children's Charity
Questions and comments from the floor with **Ray Ghouse**, Senior Health Economist, Boehringer Ingelheim
- 10.40 - 10.45 **Session Chair's closing remarks**
Andrea Jenkyns MP, Member, Health Select Committee and Chair, All-Party Parliamentary Group on Patient Safety
- 10.45 - 11.20 Coffee
- 11.20 - 11.25 **Session Chair's opening remarks**
Daniel Zeichner MP, Vice Chair, All-Party Parliamentary Group for Life Sciences
- 11.25 - 11.55 **The Accelerated Access Review and next steps for improving market access**
Nicole Mather, Director, Office for Life Sciences and Lead, Accelerated Access Review
Questions and comments from the floor
- 11.55 - 12.05 **Priorities for NHS pharmaceutical procurement: early access, fair pricing and sustainability**
Professor Karl Claxton, Professor of Economics, University of York and former Member, NICE Appraisal Committee
- 12.05 - 12.15 **Challenges for improving access to care and priorities for the Pharmaceutical Price Regulation Scheme**
Paul Catchpole, Director of Value and Access, ABPI
- 12.15 - 12.25 **The future for the Cancer Drugs Fund: access, value and evidence based strategies**
Julia Manning, Chief Executive, 2020health
- 12.25 - 12.50 Questions and comments from the floor
- 12.50 - 12.55 **Concluding remarks**
Professor Gillian Leng, Deputy Chief Executive and Director of Health and Social Care, NICE
- 12.55 - 13.00 **Session Chair's and Westminster Health Forum closing remarks**
Daniel Zeichner MP, Vice Chair, All-Party Parliamentary Group for Life Sciences
Sam Dolton, Associate Producer, Westminster Health Forum